Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Saturday, September 23, 2017
 
Recommended for you
Expect A Slow Bleed With Portola Pharma
Seeking Alpha • Richard Marzouka
FDA declines to approve J&J arthritis drug sirukumab
Reuters
VML New York Hires Fabio Seidl as Executive Creative Director
Adweek • Erik Oster
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
Seeking Alpha • Avisol Capital Partners
Pfizer, Veritas, MGH Join Xconomy’s Healthcare + A.I. Conference on Nov. 2
Xconomy • Gregory T. Huang
3 Things In Biotech You Should Learn Today: September 22, 2017
Seeking Alpha • Zach Hartman
How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs
Fortune Magazine • Sy Mukherjee
Versartis growth hormone drug fails key study, shares sink
Reuters • Reuters Staff
Versartis shares down 82%
MarketWatch • Claudiaassis
Japan Is Discovering the Power of Painkillers
Bloomberg • Kanoko Matsuyama
 
Recommended for You
Financial Regulatory Bodies, Health Finance
Expect A Slow Bleed With Portola Pharma
Seeking AlphaRichard Marzouka
Summary One approved lead drug candidate. Reversal agent for Factor Xa inhibitors with big potential. More upside with huge marketplace potential in blood disorders. Portola Pharmaceuticals Inc (PTLA) is a biopharmaceutical company with focus on thrombosis, hematologic disorders and inflammation. The stock...
Share
GlaxoSmithKline plc, Health Care Industry
FDA declines to approve J&J arthritis drug sirukumab
Reuters
(Reuters) - The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.
Share
Communication Design, Media & Advertising
VML New York Hires Fabio Seidl as Executive Creative Director
AdweekErik Oster
VML New York has welcomed Fabio Seidl as executive creative director, tasked with overseeing the office’s creative department while working with clients including New Balance, Greater Miami Convention & Visitors Bureau, Legoland Florida Resort, AMC and the United Nations. “We’re very pleased...
Share
Gilead Sciences, Health Finance
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
Seeking AlphaAvisol Capital Partners
Summary The VanEck Vectors Biotech ETF is discussed. Esperion's potential in the statin-intolerant anti-cholesterol market is discussed. Pfizer’s BAVENCIO (avelumab) is approved in Europe for the treatment of adult patients with metastatic Merkel cell carcinoma. Avisol Capital Partners, managed by Drs Udaya...
Share
Entrepreneurship, Health Care Industry
Pfizer, Veritas, MGH Join Xconomy’s Healthcare + A.I. Conference on Nov. 2
XconomyGregory T. Huang
Boston — Like a lot of fields, healthcare is riding the A.I. wave. We’re hearing about machine learning and other artificial intelligence techniques being applied to genomic analysis, drug discovery, imaging and diagnostics, patient-doctor interactions, and other clinical tasks. But there’s a...
Share
Biotechnology, Cancer
3 Things In Biotech You Should Learn Today: September 22, 2017
Seeking AlphaZach Hartman
Summary Pfizer expands its first immunotherapy approval into Europe. Audentes steps onto the clinical stage in a congenital muscle malady. Janssen and MorphoSys collab now in late-stage investigations for arthritis. Welcome to another edition of "3 Things In Biotech You Should Learn...
Share
Biotechnology, GlaxoSmithKline plc
How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs
Fortune MagazineSy Mukherjee
Vivek Ramaswamy got a pretty special present for his 32nd birthday in August: $1.1 billion in funding from SoftBank and other investors for the audacious biopharmaceutical firm he founded and leads, Roivant Sciences. That's the single biggest private financing round for a...
Share
Health Care Industry, Pfizer, Inc.
Versartis growth hormone drug fails key study, shares sink
ReutersReuters Staff
() - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent. The drug, somavaratan, is a long-acting recombinant human growth...
Share
Finance, Pfizer, Inc.
Versartis shares down 82%
MarketWatchClaudiaassis
Shares of Versartis Inc. plummet 82% late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed...
Share
Hospice & Home Care, Pfizer, Inc.
Japan Is Discovering the Power of Painkillers
BloombergKanoko Matsuyama
Sales of chronic-pain drugs may reach 188 billion yen by 2024 Pfizer, Daiichi Sankyo among drugmakers introducing products Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis,...
Share